- Report
- January 2026
- 181 Pages
Global
From €3200EUR$3,545USD£2,774GBP
€3555EUR$3,939USD£3,082GBP
- Report
- February 2026
- 250 Pages
Global
From €4052EUR$4,490USD£3,513GBP
- Report
- February 2026
- 250 Pages
Global
From €4052EUR$4,490USD£3,513GBP
- Report
- February 2026
- 250 Pages
Global
From €4052EUR$4,490USD£3,513GBP
- Report
- June 2026
- 367 Pages
Global
From €5280EUR$5,850USD£4,577GBP
- Report
- June 2025
- 150 Pages
Global
From €2436EUR$2,699USD£2,112GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2517EUR$2,789USD£2,182GBP
- Report
- April 2026
- 149 Pages
Global
From €3609EUR$3,999USD£3,129GBP
- Report
- May 2026
- 132 Pages
Global
From €4377EUR$4,850USD£3,795GBP
- Report
- August 2024
- 100 Pages
Global
From €5370EUR$5,950USD£4,656GBP
- Report
- June 2023
- 115 Pages
Global
From €4061EUR$4,500USD£3,521GBP
- Report
- May 2026
- 185 Pages
Global
From €4061EUR$4,500USD£3,521GBP
- Report
- August 2024
- 85 Pages
United States
From €3159EUR$3,500USD£2,739GBP
- Clinical Trials
- April 2025
- 50 Pages
Global
From €1354EUR$1,500USD£1,174GBP
- Report
- August 2023
- 217 Pages
Global
From €6769EUR$7,500USD£5,868GBP
- Report
- June 2025
- 400 Pages
Global
From €4467EUR$4,949USD£3,872GBP
- Report
- February 2024
- 106 Pages
Global
From €4287EUR$4,750USD£3,717GBP
- Report
- June 2025
- 122 Pages
Global
From €1977EUR$2,190USD£1,714GBP
- Report
- September 2024
- 105 Pages
Global
From €3500EUR$4,154USD£3,141GBP

Alpha-galactosidase is a type of enzyme used to treat endocrine and metabolic disorders. It is used to treat Fabry disease, a rare genetic disorder that affects the body's ability to break down certain fats. Alpha-galactosidase helps break down these fats, allowing them to be eliminated from the body. It is also used to treat other metabolic disorders, such as Gaucher disease, which is caused by an enzyme deficiency. Alpha-galactosidase is available in both oral and injectable forms.
Alpha-galactosidase is a relatively new drug in the endocrine and metabolic disorders market. It is used to treat a variety of conditions, including Fabry disease, Gaucher disease, and other metabolic disorders. It is a promising treatment option for these conditions, as it can help reduce symptoms and improve quality of life.
Several companies are involved in the Alpha-galactosidase market, including Shire, Sanofi, and Genzyme. These companies produce and market the drug, as well as provide support and resources for patients. Show Less Read more